Castle biosciences stock.

Castle Biosciences, Inc. plans to launch a genomic test by the end of 2025 that can guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions. New data shows the test's ability to distinguish between responders and non-responders to an atopic dermatitis therapy, as well as …According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...Which technical analysis tools can be used to analyze Castle Biosciences, Inc.? Check out various oscillators, moving averages and other technical ...Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, …

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.

19 Nis 2023 ... Castle Biosciences, Inc., a company improving health through innovative ... Stock BITF logo. BITF · Bitfarms Announces C$60 Million Private ...Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …

Castle Biosciences stock quote and CSTL charts. Latest stock price today and the US's most active stock market forums.The estimated Net Worth of Mara G. Aspinall is at least $2.81 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $2,014,618 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Revenue growth over the past 12 months for CASTLE BIOSCIENCES INC comes in at 55.17%, a number that bests 91.18% of the US stocks we're tracking. Stocks with similar financial metrics, market capitalization, and price volatility to CASTLE BIOSCIENCES INC are SILK, ONTF, IGC, FLGT, and BMRA. Visit CSTL's SEC page to see the company's …The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.

Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.

Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.

Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... Mr. Maetzold CSTL stock SEC Form 4 insiders trading. Derek has made over 105 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,500 units of CSTL stock worth $30,075 on 1 September 2023.. The largest trade he's ever made was exercising 65,627 units of Castle …19 Nis 2023 ... Castle Biosciences, Inc., a company improving health through innovative ... Stock BITF logo. BITF · Bitfarms Announces C$60 Million Private ...The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 8.79% so far this month. During the month of May, Castle Biosciences Inc’s stock price has reached a high of $26.70 and a low of $20.56. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $15.58. Year to date ...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …

Castle Biosciences Stock Down 0.1 %. NASDAQ:CSTL opened at $19.97 on Monday. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average ...The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued. NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.51 -0.27 (-1.37%) As of 03:38PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Max Full screen …Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ... Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...

The estimated Net Worth of Mara G. Aspinall is at least $1.28 million dollars as of 2 June 2023. Ms. Aspinall owns over 3,825 units of Castle Biosciences stock worth over $485,681 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ... registrant’s common stock on June 30, 2020, as reported by the Nasdaq Global Market. As of March 5, 2021, there were 24,978,424 shares of …Castle Biosciences Inc Stock Earnings The value each CSTL share was expected to gain vs. the value that each CSTL share actually gained. CSTL ( CSTL ) reported Q3 2023 earnings per share (EPS) of -$0.26 , beating estimates of -$0.76 by 66.32% .According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00.Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersUnder the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65.0 million in initial consideration to AltheaDx ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.

The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86. During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35. The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks.

2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)...

Contact Information. Customer Service: 866-788-9007 Option 1 [email protected]. Reimbursement: 866-788-9007 Option 3 [email protected] Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Following this news, Relmada’s stock price fell nearly 80% to close at $6.48 per share on October 13, 2022. ... Castle Biosciences, Inc. (NASDAQ: CSTL)Castle Learning Online’s products don’t come with ready-made answer keys, but they do provide instant feedback and answers once the student has gone through an assignment.Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication …The estimated Net Worth of Frank Stokes is at least $2.05 Million dollars as of 4 April 2023. Mr. Stokes owns over 4,000 units of Castle Biosciences stock worth over $556,435 and over the last 3 years he sold CSTL stock worth over $0. In addition, he makes $1,498,230 as Chief Financial Officer at Castle Biosciences.As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...Jun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months. Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 1 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 830 units of CSTL stock worth $17,355 on 10 June 2022.830 units of CSTL stock worth $17,355 on 10 June 2022.

Derek has made over 103 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 600 units of CSTL stock worth 12,060$ on 3 August 2023. 世界市場 道具 ポートフォリオ. Track performance, allocation, dividends, and risks ...Castle Biosciences Inc. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians …Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …Instagram:https://instagram. brokers para metatrader 5best inverse etf for bear marketbest fha lenders in michiganforex or futures Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ...Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ... math solver googleotcmkts wsrc Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ... Europe PMC is an archive of life sciences journal literature. charles schwab fhlb loans Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MNov 16, 2023 · Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...